Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease

• Samuel Frank,
• Karen E. Anderson,
• Hubert H. Fernandez,
• Robert A. Hauser,
• Daniel O. Claassen,
• David Stamler,
• Stewart A. Factor,
• Joohi Jimenez-Shahed,
• Hadas Barkay,
• Amanda Wilhelm,
• Jessica K. Alexander,
• Nayla Chaijale,
• Steve Barash,
• Juha-Matti Savola,
• Mark Forrest Gordon,
• Maria Chen

Affiliations

Samuel Frank

Beth Israel Deaconess Medical Center/Harvard Medical School

Karen E. Anderson

Georgetown University

Hubert H. Fernandez

Cleveland Clinic

Robert A. Hauser

University of South Florida Parkinson’s Disease and Movement Disorders Center

Daniel O. Claassen

Vanderbilt University Medical Center

David Stamler

Teva Branded Pharmaceutical Products R&D, Inc.

Stewart A. Factor

Emory University

Joohi Jimenez-Shahed

Icahn School of Medicine at Mount Sinai

Hadas Barkay

Teva Pharmaceutical Industries Ltd.

Amanda Wilhelm

Teva Branded Pharmaceutical Products R&D, Inc.

Jessica K. Alexander

Teva Branded Pharmaceutical Products R&D, Inc.

Nayla Chaijale

Teva Branded Pharmaceutical Products R&D, Inc.

Steve Barash

Teva Branded Pharmaceutical Products R&D, Inc.

Juha-Matti Savola

Teva Pharmaceuticals International GmbH

Mark Forrest Gordon

Teva Branded Pharmaceutical Products R&D, Inc.

Maria Chen

Teva Branded Pharmaceutical Products R&D, Inc.